Contact dermatitis from rifamycin.
D000287:Administration, Topical; D000328:Adult; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D010328:Patch Tests; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use
D012293:Rifampin